Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
Clinical trial NCT07213583 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07213583
- Sponsor
- Neurimmune AG
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-28
- Primary completion
- 2026-10-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.